Oregon Public Employees Retirement Fund
MYGN icon

Oregon Public Employees Retirement Fund’s Myriad Genetics MYGN Stock Holding History

Oregon Public Employees Retirement Fund’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,274
Closed -$131K – 1528
2025
Q4 		$131K Buy
21,274
+352
+2% +$2.55K ﹤0.01% 1471
2025
Q3 		$151K Sell
20,922
-200
-0.9% -$1.19K ﹤0.01% 1450
2025
Q2 		$112K Buy
21,122
+300
+1% +$1.77K ﹤0.01% 1483
2025
Q1 		$185K Sell
20,822
-600
-3% -$7.21K ﹤0.01% 1403
2024
Q4 		$294K Hold
21,422
– – 0.01% 1319
2024
Q3 		$587K Sell
21,422
-500
-2% -$13.5K 0.01% 1088
2024
Q2 		$536K Sell
21,922
-1,742
-7% -$38.2K 0.01% 1084
2024
Q1 		$505K Sell
23,664
-2,300
-9% -$49.4K 0.01% 1155
2023
Q4 		$497K Buy
25,964
+1,600
+7% +$27.7K 0.01% 1210
2023
Q3 		$391K Sell
24,364
-1,100
-4% -$20.9K 0.01% 1369
2023
Q2 		$590K Sell
25,464
-600
-2% -$13.1K 0.01% 1246
2023
Q1 		$605K Sell
26,064
-870
-3% -$17.7K 0.01% 1222
2022
Q4 		$391K Buy
26,934
+411
+2% +$7.66K 0.01% 1399
2022
Q3 		$506K Buy
26,523
+178
+0.7% +$4.08K 0.01% 1248
2022
Q2 		$479K Sell
26,345
-3,783
-13% -$78.6K 0.01% 1150
2022
Q1 		$759K Buy
30,128
+139
+0.5% +$3.56K 0.01% 1213
2021
Q4 		$828K Sell
29,989
-1,400
-4% -$40.6K 0.01% 1096
2021
Q3 		$1.01M Buy
31,389
+642
+2% +$21.3K 0.01% 985
2021
Q2 		$940K Hold
30,747
– – 0.01% 1062
2021
Q1 		$936K Buy
30,747
+600
+2% +$17K 0.01% 1056
2020
Q4 		$596K Buy
30,147
+313
+1% +$5.05K 0.01% 1166
2020
Q3 		$389K Hold
29,834
– – 0.01% 1219
2020
Q2 		$338K Hold
29,834
– – 0.01% 1249
2020
Q1 		$427K Hold
29,834
– – 0.01% 1086
2019
Q4 		$812K Buy
29,834
+700
+2% +$19.3K 0.01% 998
2019
Q3 		$834K Buy
29,134
+100
+0.3% +$2.91K 0.01% 1040
2019
Q2 		$807K Buy
29,034
+79
+0.3% +$2.23K 0.01% 1070
2019
Q1 		$961K Buy
28,955
+523
+2% +$15.9K 0.01% 966
2018
Q4 		$827K Buy
+28,432
New +$1.02M 0.01% 992

Other funds holding MYGN

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Glenview Capital Management
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Oregon Public Employees Retirement Fund's MYGN Position: Q1 2026 in Review

Oregon Public Employees Retirement Fund sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 21,274 shares — an estimated $131K sold.

Oregon Public Employees Retirement Fund first reported a position in MYGN in Q4 2018 and held it in 29 quarters. The position peaked at $1.01M in Q3 2021. 203 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Oregon Public Employees Retirement Fund reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
  • Oregon Public Employees Retirement Fund sold 21,274 Myriad Genetics shares in Q1 2026, an estimated $131K.
  • Oregon Public Employees Retirement Fund first reported a position in Myriad Genetics in Q4 2018 and held it in 29 quarters.
  • Oregon Public Employees Retirement Fund's Myriad Genetics position peaked at $1.01M in Q3 2021.
  • 203 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Oregon Public Employees Retirement Fund's 13F filing for Q1 2026, filed 29 Apr 2026.